Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

October 2019 | 40 pages | ID: M383622CE190EN
VPAResearch

Abstracts

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Drug pipeline report- 2020 is an annual R&D review of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline candidates. The report presents the current status of all major Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections therapeutic compounds. Detailed insights into Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline development, current status, companies, drug profiles and Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections preclinical and clinical trials are included.

2020 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Market Insights
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections therapies, pipeline by phase and others are included.

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Therapeutic Drug candidates
Both active and inactive Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline drug candidates are included in the report

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Clinical Trials and preclinical Studies
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline market developments
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline companies in active development
The report analyzes Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline of the below companies-

Debiopharm International SA, Destiny Pharma Plc, HyPharm GmbH, Naicons Srl, Sealife PHARMA GMBH, Tetraphase Pharmaceuticals Inc

Report Coverage

What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies
6 Companies investing in Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline from discovery stage to pre-registration phase are included

Drug profiles
Over 10 details of each Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline candidate are included

Company Profiles
Business overview and contact details of all companies operating in the industry are provided

Market Developments
News, Developments and other recent industry developments are included

Contents

1. METHICILLIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS (MSSA) INFECTIONS PIPELINE MARKET INSIGHTS, 2020

1.1 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Disease Overview
1.2 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Drug Pipeline Snapshot, 2020
  1.2.1 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drugs by Phase
  1.2.2 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drugs by Company
  1.2.3 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drugs by Mechanism of Action
  1.2.4 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drugs by Route of Administration

2. METHICILLIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS (MSSA) INFECTIONS COMPANY WISE PIPELINE DETAILS

Debiopharm International SA Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Destiny Pharma Plc Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
HyPharm GmbH Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Naicons Srl Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Sealife PHARMA GMBH Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Tetraphase Pharmaceuticals Inc Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details

3. METHICILLIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS (MSSA) INFECTIONS DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. METHICILLIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS (MSSA) INFECTIONS PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts